Web Watch

Web Watch in One Page

Five live watch items, ranked by what would actually move BAWAG's bull/bear debate. The verdict is Lean Long, Wait For Confirmation — the entry at 3.0× tangible book leaves no margin if RoTCE compresses materially, so the watch list is built around the two events that resolve the multiple (the H1 / Q3 2026 print on a clean post-Knab/Barclays base, and the Permanent TSB closing path) plus the three slower threads that could break either side of the case (PTSB minority pushback on price, Management Board insider behaviour, and the ratings/regulatory backdrop). Hard regulatory milestones get a daily cadence; slower governance and supervision threads get a weekly cadence.

Active Monitors

Rank	Watch item	Cadence	Why it matters	What would be detected
1	Permanent TSB acquisition regulatory and closing milestones	Daily	PTSB grows the balance sheet ~40% and consumes ~450 bps of CET1; the deal's closing path resets the discount/premium baked into the 3.0× P/TB multiple.	Scheme document publication, EGM date and vote outcome, Irish High Court convening or sanction orders, ECB SSM / Central Bank of Ireland / EU competition decisions and remedies, any change to the Q4 2026 / Q1 2027 closing window.
2	BAWAG quarterly earnings, RoTCE and FY2026 guidance	Daily	The H1 2026 print on 22 July and the Q3 2026 print on 21 October are the first clean post-Knab/Barclays comparable quarters and will settle whether mid-20s RoTCE is structural or cyclical.	New quarterly RoTCE, NIM, deposit beta, cost-income ratio, risk cost ratio and CET1; any revision to the FY2026 >€960m / FY2027 >€1.1bn net-profit guides or the dividend / buyback policy.
3	PTSB price contestation and shareholder activism	Daily	Sretaw (7.2% of PTSB) called €1.62bn "materially too low"; Goodbody called €2.97 "extremely disappointing"; ~€370–400m of accretion is structural badwill, not synergy.	New shareholder letters, proxy advisor recommendations, public dissent campaigns, requests for a price bump, lawsuits, EGM voting intentions, or revised offer terms.
4	BAWAG Management Board insider transactions	Daily	The CEO bought €1.19m at €147.50 on 29 April 2026, eight days after Q1 results; the Management Board owns 4.6% and has not sold a share since the 2017 IPO — a primary bull anchor.	Every new EU MAR Article 19 directors' dealing — any open-market purchase or sale by Abuzaakouk, Sirucic, Shah, Wise, O'Leary or Jestaedt; the first insider sale since the 2017 IPO would be especially material.
5	BAWAG credit ratings, ECB supervision and FMA/AML actions	Weekly	Moody's Positive outlook on the A1 rating helps fund PTSB via SRTs and MREL; the December 2024 €588k FMA AML penal order is under appeal at the Federal Administrative Court while regulators review PTSB.	New rating actions from Moody's / S&P / Fitch / DBRS, ECB SREP or Pillar 2 decisions, the BVwG ruling on the FMA AML appeal, and any Basel Committee or EBA tightening of Significant Risk Transfer rules.

Why These Five

The report's most important open questions are concentrated on three threads. Is 27% RoTCE structural or peak-cycle? Monitor 2 catches every fresh data point that resolves it — the H1 and Q3 2026 RoTCE / NIM / deposit beta / risk cost prints and any guidance revision. Will Permanent TSB close on the guided timeline at the underwritten >€250m PBT contribution? Monitors 1, 3 and 5 cover the three forces that decide it: the regulatory clock and scheme mechanics (1), Sretaw-led minority pushback that could force a price bump or block the EGM (3), and the FMA AML appeal plus any Basel-driven SRT-rule tightening that could attach remedies or lift funding cost (5). Does the alignment story hold? Monitor 4 watches the strongest non-financial bull pillar — the zero-MB-sales record since the 2017 IPO and the CEO's repeated open-market buying near the all-time high. The set deliberately excludes generic "latest BAWAG news" — every monitor traces back to a specific bull or bear claim that can flip on a single material event.